COVID and Long COVID
Sort
Whitney Gibb used to move through life at full speed. After COVID, brain fog, fatigue, and memory loss reshaped her daily life — offering a powerful window into the realities of Long COVID and the research now working to understand it.
At a recent virtual town hall, leaders of the Pacific Northwest RECOVER hub shared what they’ve learned so far about long COVID — from symptom trajectories and genetic risk to early trial results and upcoming studies — and answered questions from participants about risk factors, persistent symptoms and what comes next.
Researchers from the NIH-funded RECOVER study shared new insights on the risks of Long COVID, autoimmune links, and upcoming clinical trials during ISB’s July Town Hall.
Scientists at the Institute for Systems Biology (ISB) reveal how T cells “decide” their fate in fighting infections like COVID-19, paving the way for improved treatments for infections, cancer, and autoimmune diseases.
ISB hosted a virtual event to share updates on the ongoing RECOVER study, a national NIH-funded initiative to understand and address Long COVID.
As part of a massive nationwide effort, ISB is leading a multi-site consortium for the NIH RECOVER (Researching COVID to Enhance Recovery) Initiative. The Pacific Northwest consortium is made up of ISB, Providence, Swedish, and University of Washington School of Medicine.